201 related articles for article (PubMed ID: 36606106)
1. The Role of Biologics in Rheumatoid Arthritis: A Narrative Review.
Patel JP; Konanur Srinivasa NK; Gande A; Anusha M; Dar H; Baji DB
Cureus; 2023 Jan; 15(1):e33293. PubMed ID: 36606106
[TBL] [Abstract][Full Text] [Related]
2. Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis.
Singh JA; Hossain A; Tanjong Ghogomu E; Mudano AS; Maxwell LJ; Buchbinder R; Lopez-Olivo MA; Suarez-Almazor ME; Tugwell P; Wells GA
Cochrane Database Syst Rev; 2017 Mar; 3(3):CD012591. PubMed ID: 28282491
[TBL] [Abstract][Full Text] [Related]
3. Real-world Effectiveness of Biologic Disease-modifying Antirheumatic Drugs for the Treatment of Rheumatoid Arthritis After Etanercept Discontinuation in the United Kingdom, France, and Germany.
Li N; Betts KA; Messali AJ; Skup M; Garg V
Clin Ther; 2017 Aug; 39(8):1618-1627. PubMed ID: 28729087
[TBL] [Abstract][Full Text] [Related]
4. Biologic agents in rheumatoid arthritis: an update for managed care professionals.
Agarwal SK
J Manag Care Pharm; 2011; 17(9 Suppl B):S14-8. PubMed ID: 22073935
[TBL] [Abstract][Full Text] [Related]
5. Enzyme-linked immunosorbent assays for monitoring TNF-alpha inhibitors and antibody levels in people with rheumatoid arthritis: a systematic review and economic evaluation.
Tikhonova IA; Yang H; Bello S; Salmon A; Robinson S; Hemami MR; Dodman S; Kharechko A; Haigh RC; Jani M; McDonald TJ; Hoyle M
Health Technol Assess; 2021 Feb; 25(8):1-248. PubMed ID: 33555998
[TBL] [Abstract][Full Text] [Related]
6. Infection risk in patients undergoing treatment for inflammatory arthritis: non-biologics versus biologics.
Chiu YM; Chen DY
Expert Rev Clin Immunol; 2020 Feb; 16(2):207-228. PubMed ID: 31852268
[No Abstract] [Full Text] [Related]
7. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.
Chen YF; Jobanputra P; Barton P; Jowett S; Bryan S; Clark W; Fry-Smith A; Burls A
Health Technol Assess; 2006 Nov; 10(42):iii-iv, xi-xiii, 1-229. PubMed ID: 17049139
[TBL] [Abstract][Full Text] [Related]
8. [Biologic therapy of rheumatoid arthritis].
Damjanov N; Vojinović J
Srp Arh Celok Lek; 2009; 137(3-4):205-10. PubMed ID: 19459571
[TBL] [Abstract][Full Text] [Related]
9. Tumour necrosis factor inhibitors versus combination intensive therapy with conventional disease modifying anti-rheumatic drugs in established rheumatoid arthritis: TACIT non-inferiority randomised controlled trial.
Scott DL; Ibrahim F; Farewell V; O'Keeffe AG; Walker D; Kelly C; Birrell F; Chakravarty K; Maddison P; Heslin M; Patel A; Kingsley GH
BMJ; 2015 Mar; 350():h1046. PubMed ID: 25769495
[TBL] [Abstract][Full Text] [Related]
10. Biologic therapies and bone loss in rheumatoid arthritis.
Zerbini CAF; Clark P; Mendez-Sanchez L; Pereira RMR; Messina OD; Uña CR; Adachi JD; Lems WF; Cooper C; Lane NE;
Osteoporos Int; 2017 Feb; 28(2):429-446. PubMed ID: 27796445
[TBL] [Abstract][Full Text] [Related]
11. Comparative effectiveness of first-line tumour necrosis factor inhibitor versus non-tumour necrosis factor inhibitor biologics and targeted synthetic agents in patients with rheumatoid arthritis: results from a large US registry study.
Pappas DA; St John G; Etzel CJ; Fiore S; Blachley T; Kimura T; Punekar R; Emeanuru K; Choi J; Boklage S; Kremer JM
Ann Rheum Dis; 2021 Jan; 80(1):96-102. PubMed ID: 32719038
[TBL] [Abstract][Full Text] [Related]
12. Comparative efficacy of biologics as monotherapy and in combination with methotrexate on patient reported outcomes (PROs) in rheumatoid arthritis patients with an inadequate response to conventional DMARDs--a systematic review and network meta-analysis.
Jansen JP; Buckley F; Dejonckheere F; Ogale S
Health Qual Life Outcomes; 2014 Jul; 12():102. PubMed ID: 24988902
[TBL] [Abstract][Full Text] [Related]
13. Towards a stratified targeted approach with biologic treatments in rheumatoid arthritis: role of synovial pathobiology.
Astorri E; Nerviani A; Bombardieri M; Pitzalis C
Curr Pharm Des; 2015; 21(17):2216-24. PubMed ID: 25760296
[TBL] [Abstract][Full Text] [Related]
14. A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview.
Singh JA; Christensen R; Wells GA; Suarez-Almazor ME; Buchbinder R; Lopez-Olivo MA; Ghogomu ET; Tugwell P
CMAJ; 2009 Nov; 181(11):787-96. PubMed ID: 19884297
[TBL] [Abstract][Full Text] [Related]
15. Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation.
Stevenson M; Archer R; Tosh J; Simpson E; Everson-Hock E; Stevens J; Hernandez-Alava M; Paisley S; Dickinson K; Scott D; Young A; Wailoo A
Health Technol Assess; 2016 Apr; 20(35):1-610. PubMed ID: 27140438
[TBL] [Abstract][Full Text] [Related]
16. Bioboosters in the treatment of rheumatic diseases: a comprehensive review of currently available biologics in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis.
Cantini F; Nannini C; Niccoli L
Open Access Rheumatol; 2009; 1():163-178. PubMed ID: 27789989
[TBL] [Abstract][Full Text] [Related]
17. Rheumatoid arthritis.
Smolen JS; Aletaha D; McInnes IB
Lancet; 2016 Oct; 388(10055):2023-2038. PubMed ID: 27156434
[TBL] [Abstract][Full Text] [Related]
18. Down-titration and discontinuation strategies of tumor necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity.
van Herwaarden N; den Broeder AA; Jacobs W; van der Maas A; Bijlsma JW; van Vollenhoven RF; van den Bemt BJ
Cochrane Database Syst Rev; 2014 Sep; (9):CD010455. PubMed ID: 25264908
[TBL] [Abstract][Full Text] [Related]
19. [New drugs and treatment strategies for rheumatoid arthritis].
Fantini F
Recenti Prog Med; 2003 Sep; 94(9):361-79. PubMed ID: 12942798
[TBL] [Abstract][Full Text] [Related]
20. Biologics in Inflammatory and Immunomediated Arthritis.
Luchetti MM; Benfaremo D; Gabrielli A
Curr Pharm Biotechnol; 2017; 18(12):989-1007. PubMed ID: 29278210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]